Edasalonexent

SKU: orb1707344

Description

Edasalonexent (CAT-1004) is an orally administered small molecule inhibitor of NF-κB, developed for research into Duchenne muscular dystrophy (DMD). It has been investigated in both in vitro models and in vivo preclinical studies to assess its potential to modulate inflammation and disease progression associated with DMD.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1204317-86-1
• MW: 490.68
• Purity: >99.99% (May vary between batches)
• Formula: C₃₁H₄₂N₂O₃
• SMILES: CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O
• Target: NF-κB
• Solubility: DMSO:80 mg/mL (163.04 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2.5 mg/mL (5.09 mM)

Bioactivity

• In Vivo:
  In vivo, Edasalonexent effectively improves the phenotype of mdx mice in terms of activity, muscle mass and function, injury, inflammation, fibrosis, and cardiac pathology associated with voluntary wheel running.
  Read more...
• In Vitro:
  Edasalonexent effectively inhibits the pathogenic NF-κB subunit p65/RelA in vitro.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Edasalonexent, CAT1004, CAT-1004, CAT 1004, NFkB, NF-kB, NFκB, NF-κB

Compound Identifiers

PubChem CID

44626120